Upstate Active Clinical Trials
Study Title:
ANBL1531 - A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)What is the purpose of the study? (in Layman's terms, please describe the study)
Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)Upstate Institutional Review Board (IRB) Number:
1601784Study/Protocol ID:
ANBL1531Study Phase:
IIIPatient Age Group:
ChildrenPrincipal Investigator:
Melanie A ComitoWho is eligible?
Patient must be ≥ 365 days and ≤ 30 years of age at diagnosis.What is involved if I participate?
- How long is the study?
until accrual is met - Is transportation provided or reimbursed?
No - Is parking provided or reimbursed?
Yes - What tests and procedures are involved?
surgery, transplant, blood draws, imaging, radiation therapy
Where will the study take place?
SUNY Upstate Medical UniversityOther Information:
N/AWho can I contact for more information?
Name: Karen B Bilynsky
Phone: 315-464-7601
Email: [email protected]